publication . Article . 1995

Treatment of HIV-associated Kaposi's sarcoma with paclitaxel

M.W. Saville; J. Lietzau; J.M. Pluda; W.H. Wilson; R.W. Humphrey; E. Feigel; S.M. Steinberg; S. Broder; R. Yarchoan; J. Odom; ...
Open Access
  • Published: 01 Jul 1995
Abstract
Abstract We investigated whether paclitaxel was active in AIDS-associated Kaposi's sarcoma. We gave 135 mg/m 2 intravenously over 3 hours every 21 days. Follow-up is available on the first 20 patients, most of whom had advanced Kaposi's sarcoma and severe immuno-compromise. Neutropenia was the most frequent dose-limiting toxic effect; novel toxic effects included late fevers, rash, and eosinophilia. Creatinine increased in 2 patients and 1 patient had cardiomyopathy. There were 13 partial responses (65%, 95% Cl 41-85%). All 5 patients with pulmonary involvement responded. Paclitaxel appears to be active against Kaposi's sarcoma as a single agent. Further studies...
Subjects
free text keywords: General Medicine, Kaposi's sarcoma, medicine.disease, medicine, Neutropenia, Paclitaxel, chemistry.chemical_compound, chemistry, Eosinophilia, medicine.symptom, Immunopathology, Rash, Sarcoma, Surgery, medicine.medical_specialty, business.industry, business, Chemotherapy, medicine.medical_treatment
Related Organizations
Download fromView all 2 versions
ZENODO
Article . 1995
Provider: ZENODO
The Lancet
Article
Provider: UnpayWall
The Lancet
Article
Provider: Crossref
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . 1995

Treatment of HIV-associated Kaposi's sarcoma with paclitaxel

M.W. Saville; J. Lietzau; J.M. Pluda; W.H. Wilson; R.W. Humphrey; E. Feigel; S.M. Steinberg; S. Broder; R. Yarchoan; J. Odom; ...